Zimmer Biomet Holdings reports Q1 2026 results on May 22 carrying the fresh bruise of a 13% one-day drop from its prior quarterly print — and options traders are already moving for cover.
The clearest signal heading into Thursday's release is in the options market. The put/call ratio has jumped to 0.79, more than two standard deviations above its 20-day average of 0.72. That is not a crowded bear position — but relative to where options sentiment has been sitting over the past month, the defensive tilt is real. Meanwhile, the borrow market tells an entirely different story: availability is wide open at 766% of short interest, with cost to borrow running below 0.5%. Short interest itself is modest at 4.8% of free float, and while it ticked up about 8% over the past month, it has pulled back nearly 2.5% across the most recent week. There is no meaningful short squeeze pressure here, and no sign that bears are piling in ahead of the event.
The debate around Zimmer Biomet is less about short-term positioning and more about whether the company can restore credibility after a damaging prior quarter. The last earnings print on April 28 delivered a 13.5% single-day decline and a further 10.3% loss over the following five days — one of the sharpest post-earnings reactions among large medical device names in recent memory. The Street's response was swift and uniform: every major firm covering the stock cut its price target on April 29, with JPMorgan lowering to $95 and Barclays maintaining an Underweight at $94. The consensus still technically reads "buy," but with a mean target of $98.52 against a current price of $83.70, a healthy chunk of that implied upside reflects targets that were set before the April drawdown. Bears point to margin disappointments, a tariff benefit that pulled forward earnings recognition and may create headwinds in future quarters, and execution uncertainty as the company transitions toward a direct salesforce. Bulls counter that ZBH holds dominant reconstructive market share in multiple regions, is building a credible pipeline of new products, and trades at a PE of under 10x — a multiple that prices in a lot of pessimism.
The stock has bounced roughly 1.7% over the past week after a 13% slide over the past month, suggesting the market has partially stabilised around current levels. Peer behaviour is mixed: SYK has gained 7.5% on the week, offering a reminder that medtech money is moving — just not yet back into ZBH. Days to cover clock at 8.6 sessions, which means any meaningful short covering would take time to work through the float, but with availability this loose the conditions for a squeeze are absent.
The May 22 print is therefore a direct test of whether Zimmer Biomet can deliver cleaner underlying margins and more reliable guidance after a quarter that rattled confidence — or whether the structural execution challenges flagged by the bear case are taking longer to resolve than even cautious forecasts assumed.
See the live data behind this article on ORTEX.
Open ZBH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
